Lumenis Announces Nasdaq Hearing Date
06 December 2003 - 1:18AM
PR Newswire (US)
Lumenis Announces Nasdaq Hearing Date YOKNEAM, Israel, Dec. 5
/PRNewswire-FirstCall/ -- Lumenis Ltd. announced today that the
hearing with a Nasdaq Listing Qualifications Panel has been set for
December 18, 2003. As previously announced, Lumenis had intended to
appeal at the hearing a letter received from the Staff of Nasdaq
stating its securities are subject to delisting since the interim
financials in the Company's Form 10-Q for the quarter ended
September 30, 2003 had not been reviewed by the Company's
independent auditors in accordance with SEC Rules due to an ongoing
independent investigation being conducted by its Audit Committee.
Pending the hearing and the Panel's determination, the Company's
shares will continue to be listed on The Nasdaq National Market and
quoted under the trading symbol LUMEE. The Audit Committee is
working expeditiously to complete its investigation. About Lumenis
Lumenis develops, manufactures, and markets state-of-the-art
proprietary laser and intense pulsed light devices. Its systems are
used in a variety of aesthetic, ophthalmic, surgical and dental
applications, including skin treatments, hair removal, non-invasive
treatment of vascular lesions and pigmented lesions, acne,
psoriasis, ENT, gynecology, urinary lithotripsy, benign prostatic
hyperplasia, open angle glaucoma, diabetic retinopathy, secondary
cataracts, age-related macular degeneration, vision correction,
neurosurgery, dentistry and veterinary. For more information about
the Company and its products log on to http://www.lumenis.com/ .
The statements in this press release that are not historical facts
are forward-looking statements which are subject to risks and
uncertainties. The Company's actual results could differ materially
from those anticipated in the forward looking statements based on a
variety of factors, including, among others: uncertainties with
respect to market acceptance of the Company's products, obtaining
regulatory approvals for new products or for the sale of existing
products in new markets and enforcement of intellectual property
rights; risks associated with competition and competitive pricing
pressures, economic conditions generally, the Company's
international operations and the Company's ability to integrate its
operations with those of acquired businesses; the outcome of the
Securities and Exchange Commission investigation and several
securities class action lawsuits to which the Company is subject;
uncertainties relating to the Company's continuing liquidity; and
other risks detailed from time to time in the reports filed by
Lumenis with the SEC, including its annual report on Form 10-K and
quarterly reports on Form 10-Q. Contact: Kevin Morano CFO
212-515-4187/ DATASOURCE: Lumenis Ltd. CONTACT: Kevin Morano, CFO
of Lumenis Ltd., +1-212-515-4187 Web Site: http://www.lumenis.com/
Copyright
Lumenis (NASDAQ:LUMEE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lumenis (NASDAQ:LUMEE)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Lumenis Ltd. (MM) (NASDAQ): 0 recent articles
More Lumenis Ltd. (MM) News Articles